CDCA7L (cell division cycle associated 7 like) is a c-Myc-interacting transcriptional regulator implicated in cell proliferation and cancer progression. CDCA7L functions as an oncogenic mediator in multiple malignancies. In medulloblastoma, CDCA7L (also known as JPO2) promotes metastatic phenotypes through PI3K/AKT signaling via interaction with LEDGF/p75 1. In glioma, CDCA7L promotes proliferation by targeting CCND1 (cyclin D1), and knockdown of CDCA7L inhibits cell cycle progression and invasion 23. High CDCA7L expression correlates with poor prognosis and unfavorable survival outcomes in glioma and multiple myeloma 34. CDCA7L has been identified as a tertiary lymphoid structure-related gene associated with hepatocellular carcinoma (HCC) risk, with genetic variants linked to HBV reactivation after liver transplantation 56. Notably, genome-wide association studies identified SNPs in CDCA7L linked to multiple myeloma susceptibility, where increased CDCA7L expression, mediated by IRF4 binding, promotes proliferation and is associated with adverse survival 4. Recently, E2F2 was shown to upregulate CDCA7L expression to promote wound healing in diabetic foot ulcers 7. DNA methylation of CDCA7L has been associated with polyunsaturated fatty acid intake 8.